{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T07:06:44Z","timestamp":1762067204021},"reference-count":5,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10526,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1983,10]]},"abstract":"<jats:p>6\u2010Mercaptopurine is extensively used in the treatment of childhood lymphoblastic leukaemia to prolong the duration of remission achieved with other drugs. The response to remission maintenance therapy varies widely. We investigated the relationship between red blood cell 6\u2010 thioguanine nucleotide, a metabolite of 6\u2010mercaptopurine, and myelosuppression in 22 children with acute lymphoblastic leukaemia in remission. The peripheral neutrophil count was used as an index of myelosuppression. 6\u2010Mercaptopurine dose was related to 6\u2010thioguanine nucleotide concentration (r = 0.4; P less than 0.001; n = 90; y = 18.51 + 0.36 x). Large individual variations around the regression line are observed. Neither 6\u2010mercaptopurine dose nor 6\u2010thioguanine nucleotide concentration was related to the neutrophil count at the time of sampling (day 0) or 7 days later. Both 6\u2010mercaptopurine dose and 6\u2010 thioguanine nucleotide concentration correlated with the neutrophil count at day 14 (r = \u22120.33; P less than 0.01; n = 90 and r = \u22120.3; P less than 0.01; n = 90 respectively). This delay is compatible with a cytotoxic action on bone marrow stem cells. Excluding children with other, uncontrolled, potentially myelosuppressive influences the correlation between 6\u2010thioguanine nucleotide concentration and neutropenia improved (r = \u22120.6; P less than 0.001; n = 37). A significant degree of neutropenia was observed by day 14 if the 6\u2010 thioguanine nucleotide concentration (day 0) was greater than 210 pmol\/8 \u00d7 10(8) RBCs. The assay of 6\u2010thioguanine nucleotide may highlight those individuals with pharmacokinetic resistance. Two children on continuous high dose 6\u2010mercaptopurine, had low red blood cell 6\u2010thioguanine nucleotide concentrations and neutropenia was not observed.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1983.tb02178.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T18:56:40Z","timestamp":1343329000000},"page":"359-363","source":"Crossref","is-referenced-by-count":156,"title":["Childhood leukaemia: a relationship between intracellular 6\u2010 mercaptopurine metabolites and neutropenia."],"prefix":"10.1111","volume":"16","author":[{"given":"L","family":"Lennard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CA","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JS","family":"Lilleyman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JL","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"1100","article-title":"Hematologic abnormalities after oral trimethoprimsulfamethoxazole therapy in children","volume":"135","author":"ASMAR B.I.","year":"1981","journal-title":"Am. J. Dis. Child."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1982.175"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1983.tb04255.x"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02178.x"},{"key":"e_1_2_1_6_1","first-page":"738","article-title":"A biochemical mechanism for the delayed cytotoxic reaction of 6\u2010mercaptopurine","volume":"34","author":"TIDD D.M.","year":"1974","journal-title":"Cancer Res."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1983.tb02178.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1983.tb02178.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T05:46:00Z","timestamp":1697780760000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1983.tb02178.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1983,10]]}},"alternative-id":["10.1111\/j.1365-2125.1983.tb02178.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02178.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,10]]}}}